Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).

The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

SOHO 2022 | Challenges with implementing CARs in CLL and the promise of allogeneic products

Nitin Jain • 29 Sep 2022
SOHO 2022
Chronic Lymphocytic Leukemia Leukemia Lymphoma Non-Hodgkin Lymphoma CAR-T Lisocabtagene maraleucel

In this video, Nitin Jain, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the use of autologous CAR-T cell products in the treatment of chronic lymphocytic leukemia (CLL), and challenges in this space. Dr Jain also highlights the promise of allogeneic CARs, and ongoing trials evaluating these agents. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Nitin Jain

Value of genomic assessment in guiding first-line CLL treatment: FISH, IGHV, and TP53 testing
1:27
Value of genomic assessment in guiding first-line CLL treatment: FISH, IGHV, and TP53 testing
Nitin Jain • 1 Oct 2026
Sequencing pirtobrutinib in CLL: overcoming covalent BTKi resistance and future first-line use
2:42
Sequencing pirtobrutinib in CLL: overcoming covalent BTKi resistance and future first-line use
Nitin Jain • 1 Oct 2026
Pirtobrutinib and venetoclax in relapsed CLL: factors guiding treatment selection and sequencing
2:14
Pirtobrutinib and venetoclax in relapsed CLL: factors guiding treatment selection and sequencing
Nitin Jain • 1 Oct 2026
Phase II PIVOT-CLL: pirtobrutinib, venetoclax, and obinutuzumab triplet vs doublet therapy in CLL
2:04
Phase II PIVOT-CLL: pirtobrutinib, venetoclax, and obinutuzumab triplet vs doublet therapy in CLL
Nitin Jain • 1 Oct 2026

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals